NICOLE TRINGALI: Open Payments
NPI 1043511074 · NEW BEDFORD, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,904 in 115 payments from 15 companies in 2025. Trend: 2023 $1,526 · 2024 $1,597 · 2025 $1,904
Food & beverage: $1,904
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 23 | $374 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 26 | $314 |
| ABBVIE INC. | 23 | $304 |
| Vanda Pharmaceuticals Inc. | 11 | $221 |
| Alkermes, Inc. | 8 | $139 |
| Supernus Pharmaceuticals, Inc. | 5 | $109 |
| Lundbeck LLC | 3 | $77 |
| Teva Pharmaceuticals USA, Inc. | 3 | $76 |
| E.R. Squibb & Sons, L.L.C. | 3 | $66 |
| Axsome Therapeutics, Inc. | 2 | $51 |
Products named: REXULTI, CAPLYTA, VRAYLAR, FANAPT, ARISTADA, Qelbree, COBENFY, Auvelity.
Industry payments across MA — which companies pay providers there.
